TELA Bio announces the U.S. launch of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ open hernia mesh fixation liquid adhesives. LIQUIFIX FIX8™ is indicated for minimally invasive femoral and inguinal hernia repairs and LIQUIFIX Precision™ is indicated for open femoral and inguinal hernia repairs. The LIQUIFIX™ liquid adhesives are the only FDA-approved devices that affix mesh and approximate peritoneal tissue with liquid anchors.
Eliminate the Need for Mechanical Fixation
LIQUIFIX™ hernia mesh fixation devices eliminate the need for penetrating mechanical tacks, sutures, or staples by delivering a liquid adhesive that allows for precise and controlled mesh fixation. The products are designed to reduce the risk of mechanical tissue trauma as they do not breach patient tissue, allowing surgeons to affix the mesh and minimize risks of complications.
The LIQUIFIX™ products may offer greater utility for surgical mesh in inguinal hernia repair by enabling mesh fixation to sensitive areas, such as the “triangle of doom” and “triangle of pain” – regions containing sensitive arteries, veins, and nerves where traditional traumatic fixation methods could result in major vascular or nerve injuries leading to chronic pain.
“
Aligned with our mission to prioritize the preservation and restoration of the patient’s own anatomy, this novel device is a natural addition to our fast-growing commercial portfolio,” said Antony Koblish, president and chief executive officer of TELA Bio. “
We’re excited to help surgeons across the U.S. advance the future of hernia repair fixation in robotic, laparoscopic, and open cases with this atraumatic approach.”
“
Based on my experience, the device is easy to use and is safe and effective,” said Mr. Paul Wilson, consultant general surgeon, who has used LIQUIFIX™ in over 1500 laparoscopic hernia repairs in the United Kingdom (U.K.). “
The fixation strength is very impressive. I have seen a significant benefit to the patient, with a major reduction in both acute post-op pain and chronic pain after surgery. This has been a game-changer for me.”
Collaboration for the U.S. Market Expansion
LIQUIFIX™ products are manufactured by U.K.-based Advanced Medical Solutions Limited (AMS), a specialist in tissue-healing technologies. AMS entered into an agreement with TELA Bio in 2023 to commercialize the LIQUIFIX™ products in the U.S., leveraging the company’s rapidly expanding hernia repair specialty salesforce and its focus on new technologies.
“
Given the consistent strong performance of the LIQUIFIX™ products in Europe and other international markets over the past three years, we look forward to working with TELA Bio to grow adoption in the U.S.,” said Chris Meredith, chief executive officer of AMS.
Source: TELA Bio